

Figure S1. Hematoxylin and Eosin staining of 7 µm sections of thyroids from untreated WT, *FOXE1*^{+/-}, *BRAF FOXE1*^{+/+} and *BRAF FOXE1*^{+/-} mice. Each image is representative of six different images.

A

| Genotype | No. of mice per treatment | |
|--|---------------------------|------|
| | NT | +DOX |
| WT | 6 | 6 |
| <i>FOXE1</i>^{+/-} | 6 | 6 |
| <i>BRAF FOXE1</i>^{+/+} | 6 | 6 |
| <i>BRAF FOXE1</i>^{+/-} | 6 | 6 |


B

Figure S2. (A) Twelve mice of each useful genotype were divided in two experimental groups of six animals per group: the untreated group (NT) and the group fed with a 2500 mg/kg doxycycline supplemented fodder for one week (+DOX). (B). Hematoxylin and Eosin staining of 7 µm sections of WT and *FOXE1*^{+/-} thyroid after one week of doxycycline administration. 10X magnification is shown. Each image is representative of six different images.




Figure S3. IHC staining for Ki67 (upper panel) and Cleaved Caspase-3 (bottom panel) was performed on 7 µm section of thyroids from WT and *FOXE1*^{+/-} mice after one week of doxycycline treatment. Hematoxylin staining of nuclei was then performed. 20X magnifications are shown. Each image is representative of six different images.




Figure S4. (A). IHC staining for PAX8 (upper panel) and TG (bottom panel) was performed on 7 μ m section of thyroids from WT and *FOXE1*^{+/-} mice after one week of doxycycline treatment. 20X magnifications are shown. Each image is representative of six different images. (B). Total RNA was extracted from pooled thyroids of six WT and six *FOXE1*^{+/-} mice, either treated and untreated (NT). Differentiation markers were analyzed by quantitative RT-PCR. Results are normalized using β -actin and reported as the fold change ($2^{-\Delta\Delta C_t}$) of WT and *FOXE1*^{+/-} treated mice respect to the untreated mice with same genotype. Means \pm SD are shown.